Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Psoriatic Arthritis - Pipeline Review, H1 2015” to its store. The report provides an overview of the Psoriatic Arthritis’s therapeutic pipeline.

Psoriatic Arthritis Therapeutic Pipeline Review H1 2015

Psoriatic Arthritis Therapeutic Pipeline Review H1 2015

Past News Releases

RSS

The report “Psoriatic Arthritis - Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-arthritis-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. Companies discussed in this Psoriatic Arthritis - Pipeline Review, H1 2015 report include AbbVie Inc., AbGenomics International, Inc., Alder Biopharmaceuticals Inc., Amgen Inc., Avesthagen Limited, Biocon Limited, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Inc., Coherus BioSciences, Inc., Covagen AG, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Genor BioPharma Co., Ltd., Inbiopro Solutions Pvt. Ltd., Innovent Biologics, Inc., Johnson & Johnson, Kineta, Inc., Mabion SA, Momenta Pharmaceuticals, Inc., Novartis AG, Oncobiologics, Inc., Panacea Biotec Limited, Pfizer Inc., Sandoz International GmbH, Swedish Orphan Biovitrum AB, Therapeutic Proteins International, LLC and UCB S.A.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are abatacept (recombinant), AbGn-168H, ABT-122, adalimumab biosimilar, anakinra (recombinant), apremilast, bimekizumab, brodalumab, clazakizumab, COVA-322, dalazatide, etanercept biosimilar, golimumab, golimumab biosimilar, guselkumab, IBI-303, IBPM-004AM, IBPM-005IX, infliximab biosimilar, INV-17, itolizumab, ixekizumab, Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis, secukinumab and tofacitinib.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=394571 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Psoriatic Arthritis, H1 2015 12
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2015 26
Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2015 27
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2015 28
Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2015 29
Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2015 30
Psoriatic Arthritis - Pipeline by Avesthagen Limited, H1 2015 31
Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2015 32
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2015 33
Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2015 34
Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2015 35
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2015 36
Psoriatic Arthritis - Pipeline by Covagen AG, H1 2015 37
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2015 38
Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 39
Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2015 40
Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 41
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2015 42
Psoriatic Arthritis - Pipeline by Johnson & Johnson, H1 2015 43
Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2015 44
Psoriatic Arthritis - Pipeline by Mabion SA, H1 2015 45
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 46
Psoriatic Arthritis - Pipeline by Novartis AG, H1 2015 47
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2015 48
Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2015 49
Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2015 50
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2015 51
Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2015 52
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2015 53
Psoriatic Arthritis - Pipeline by UCB S.A., H1 2015 54
Assessment by Monotherapy Products, H1 2015 55
Number of Products by Stage and Target, H1 2015 57
Number of Products by Stage and Mechanism of Action, H1 2015 59
Number of Products by Stage and Route of Administration, H1 2015 61
Number of Products by Stage and Molecule Type, H1 2015 63
Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2015 129
Psoriatic Arthritis - Dormant Projects, H1 2015 179
Psoriatic Arthritis - Discontinued Products, H1 2015 180

List of Figures
Number of Products under Development for Psoriatic Arthritis, H1 2015 12
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Products, H1 2015 21
Assessment by Monotherapy Products, H1 2015 55
Number of Products by Top 10 Targets, H1 2015 56
Number of Products by Stage and Top 10 Targets, H1 2015 56
Number of Products by Top 10 Mechanism of Actions, H1 2015 58
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 58
Number of Products by Top 10 Routes of Administration, H1 2015 60
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 61
Number of Products by Top 10 Molecule Types, H1 2015 62
Number of Products by Stage and Top 10 Molecule Types, H1 2015 63

Explore more reports on Arthritis therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/arthritis-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on